- |||||||||| Xtandi (enzalutamide) / Pfizer, Astellas, Bausch Health, 4SC-205 / 4SC
[VIRTUAL] KIF11-AR dual inhibition: a novel strategy to reverse endocrine therapy resistance in CRPC () - May 30, 2021 - Abstract #EACR2021EACR_3330;
These led us to hypothesize that KIF11 and the AR form a positive feedback loop in PCa promoting cell proliferation, the development of CRPC and therapy resistance. Furthermore, we demonstrate that KIF11 inhibition effectively enhances the sensitivity of CRPC cells and reverses enzalutamide resistance both, in vitro and in vivo Conclusion Altogether, we conclude that KIF11 overexpression plays an important role in the progression of CRPC and therapy resistance and we propose that a dual inhibition of the AR pathway and KIF11 could enhance the sensitivity of prostate tumors to enzalutamide giving a good rationale for a combination therapy for the treatment of CRPC patients
- |||||||||| Xtandi (enzalutamide) / Pfizer, Astellas, Bausch Health, 4SC-205 / 4SC
[VIRTUAL] KIF11-AR dual inhibition: a novel strategy to reverse endocrine therapy resistance in CRPC () - May 30, 2021 - Abstract #EACR2021EACR_3329;
These led us to hypothesize that KIF11 and the AR form a positive feedback loop in PCa promoting cell proliferation, the development of CRPC and therapy resistance. Furthermore, we demonstrate that KIF11 inhibition effectively enhances the sensitivity of CRPC cells and reverses enzalutamide resistance both, in vitro and in vivo Conclusion Altogether, we conclude that KIF11 overexpression plays an important role in the progression of CRPC and therapy resistance and we propose that a dual inhibition of the AR pathway and KIF11 could enhance the sensitivity of prostate tumors to enzalutamide giving a good rationale for a combination therapy for the treatment of CRPC patients
- |||||||||| Xtandi (enzalutamide) / Pfizer, Astellas, Bausch Health, 4SC-205 / 4SC
[VIRTUAL] KIF11-AR dual inhibition: a novel strategy to reverse endocrine therapy resistance in CRPC () - May 30, 2021 - Abstract #EACR2021EACR_3328;
These led us to hypothesize that KIF11 and the AR form a positive feedback loop in PCa promoting cell proliferation, the development of CRPC and therapy resistance. Furthermore, we demonstrate that KIF11 inhibition effectively enhances the sensitivity of CRPC cells and reverses enzalutamide resistance both, in vitro and in vivo Conclusion Altogether, we conclude that KIF11 overexpression plays an important role in the progression of CRPC and therapy resistance and we propose that a dual inhibition of the AR pathway and KIF11 could enhance the sensitivity of prostate tumors to enzalutamide giving a good rationale for a combination therapy for the treatment of CRPC patients
- |||||||||| Xtandi (enzalutamide) / Pfizer, Astellas, Bausch Health, 4SC-205 / 4SC
[VIRTUAL] KIF11-AR dual inhibition: a novel strategy to reverse endocrine therapy resistance in CRPC () - May 30, 2021 - Abstract #EACR2021EACR_3327;
These led us to hypothesize that KIF11 and the AR form a positive feedback loop in PCa promoting cell proliferation, the development of CRPC and therapy resistance. Furthermore, we demonstrate that KIF11 inhibition effectively enhances the sensitivity of CRPC cells and reverses enzalutamide resistance both, in vitro and in vivo Conclusion Altogether, we conclude that KIF11 overexpression plays an important role in the progression of CRPC and therapy resistance and we propose that a dual inhibition of the AR pathway and KIF11 could enhance the sensitivity of prostate tumors to enzalutamide giving a good rationale for a combination therapy for the treatment of CRPC patients
|
